COVID-19 — China
Arturo Casadevall, chair of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, said the FDA decision resolves “a major health equity issue”. Casadevall, who proposed the treatment strategy in a [27 Feb 2020] Wall Street Journal op-ed, shared 4 key points with GHN this morning:
“Plasma was already freely available provided that physicians registered with the FDA under the prior mechanism known as the extended access protocol. [But] it was hard for
…
